Evolent Health Hits New 52-Week Low at $5.97 Amidst Major Decline

Evolent Health, Inc. has reached a new 52-week low, trading at USD 5.97 on November 6, 2025. This marks a significant decline for the microcap company, which has seen its stock price plummet by 74.7% over the past year, contrasting sharply with the S&P 500's performance of 17.53% during the same period.
The company's market capitalization stands at USD 1,151 million, and it operates within the miscellaneous industry. Evolent Health has reported negative financial results for three consecutive quarters, with a pre-tax profit of USD -7.73 million, reflecting a staggering decline of 355.12%. Additionally, the net profit has dropped to USD -6.9 million, a decrease of 311.27%. The operating cash flow for the year is also concerning, recorded at USD -33.32 million.

With a return on equity of -10.28% and a price-to-book ratio of 1.28, Evolent Health's financial metrics indicate challenges in management efficiency and profitability. The stock's performance has consistently underperformed against the S&P 500 over the last three years, raising concerns about its market position and future viability.